New Risk • Jul 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-AU$2.2m). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (AU$73k revenue, or US$51k). Market cap is less than US$10m (AU$5.89m market cap, or US$4.12m). Announcement • Jun 27
Imagion Biosystems Limited announced that it expects to receive AUD 3.75 million in funding from CPS Capital Group Pty. Ltd. Imagion Biosystems Limited announced that it will issue AUD 3.75 million in a round of funding on June 25, 2026. The transaction was led by new investor CPS Capital Group Pty. Ltd. The company will receive funding in two tranches, Tranche 1 comprises 49.3 million shares issued at AUD 0.012 per share. Tranche 2 is expected to raise the remaining AUD 3.2 million, subject to shareholder approval. Announcement • Jun 25
Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.85 million. Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.85 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 49,346,051
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 263,153,949
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,333,333
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Transaction Features: Subsequent Direct Listing Announcement • Jun 02
Imagion Biosystems Ind Application for Magsense Phase 2 Clinical Trial Clears Fda Review Imagion Biosystems Ltd. announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND) application, issuing a “Study May Proceed” letter for Phase 1b/2 clinical trials of the MagSense Imaging Agent in HER2+ breast cancer. MagSense is a first-of-its-class molecular MRI (mMRI) imaging agent that uses non-radioactive, bio-safe nanoparticles to help clinicians detect cancer earlier and with greater precision. Phase 1b/2 will be a combined trial designed to confirm the safety profile (Phase 1b) and evaluate efficacy in detecting nodal metastases (Phase 2) in patients with HER2+ breast cancer. Dr. Mohammad Eghtedari, section chief of Women's Imaging at City of Hope Cancer Center in Los Angeles, will serve as the trial’s principal investigator (PI). Eghtedari previously participated as an independent reviewer of MagSense in the company’s Phase I trial. The company expects the trial to yield insights into the potential impact on cost of care, patient outcomes, and clinical value. Paired with quantitative imaging techniques, the trial may produce critical training data for AI diagnostic tools. Conventional imaging can identify regions of interest using anatomical or morphological features, but without molecular specificity, cannot reliably differentiate benign from malignant tumors. MagSense uses targeted nanoparticles to increase imaging specificity, making it easier for clinicians to make diagnoses with certainty. The platform technology’s applications extend beyond breast cancer—Imagion has conducted pre-clinical studies of two additional imaging agents that target prostate and ovarian cancers, which will be prepared for IND-enabling studies. Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Nina Webster was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • May 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.0m free cash flow). Negative equity (-AU$2.2m). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (AU$73k revenue, or US$53k). Market cap is less than US$10m (AU$7.85m market cap, or US$5.69m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). Board Change • May 01
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Nina Webster was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 07
Imagion Biosystems Limited, Annual General Meeting, May 26, 2026 Imagion Biosystems Limited, Annual General Meeting, May 26, 2026. Announcement • Feb 04
Imagion Biosystems Ltd. Lodges IND with FDA for Phase 2 Trial of MagSense HER2 Targeting Imaging Agent Imagion Biosystems Ltd. announced that the company has progressed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense®? targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients. MagSense®? is a first-of-its-class molecular MRI (mMRI) platform technology that uses iron oxide nanoparticles with custom moieties (e.g., antibodies) to target specific disease biomarkers. Unlike general purpose contrast agents, MagSense®? particles are only detected when and where cancer is present. Using MRI, the presence of iron oxide produces a significant, identifiable change in image contrast, empowering clinicians with better information for diagnosis and treatment planning. Based on historical FDA review timelines, the company anticipates enrollment for the Phase 2 trial could begin as early as first quarter 2026. The company has selected and engaged all required strategic trial partners to manage the study and has begun the process of clinical study site engagement and progressing study logistics in compliance with Good Clinical Practices. Board Change • Dec 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Nina Webster was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 01
Imagion Biosystems Limited Appoints Nina Webster as Non- Executive Director, Effective 1 September 2025 Imagion Biosystems Limited announced the appointment of Dr. Nina Webster as a Non-Executive Director to the Board, effective 1 September 2025. Dr. Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd. Formerly the Commercial Director for Acrux Limited and Director of Commercialisation and Intellectual Property for Immuron Limited, Nina brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Dr. Webster holds a Ph.D in Pharmaceutics, a Bachelor's degree in Pharmacology, a Master's degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited. The addition of Dr. Webster to the IBX Board of Directors will further strengthen the Board's capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies. Reported Earnings • Aug 29
First half 2025 earnings released: AU$0.008 loss per share (vs AU$0.047 loss in 1H 2024) First half 2025 results: AU$0.008 loss per share. Revenue: AU$25.7k (down 98% from 1H 2024). Net loss: AU$1.66m (loss widened 8.8% from 1H 2024). New Risk • Aug 28
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: AU$1.1m (US$689k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-AU$3.9m). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Revenue is less than US$1m (AU$1.1m revenue, or US$689k). Market cap is less than US$10m (AU$3.94m market cap, or US$2.57m). Board Change • Aug 18
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director & Company Secretary Melanie Leydin was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Aug 04
Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 223,333,333
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,000,000
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Apr 01
Imagion Biosystems Limited, Annual General Meeting, May 30, 2025 Imagion Biosystems Limited, Annual General Meeting, May 30, 2025. Board Change • Feb 04
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director & Company Secretary Melanie Leydin was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director & Company Secretary Melanie Leydin was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 13
Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,250,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Nov 08
Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million. Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,250,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Aug 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.5m free cash flow). Shares are highly illiquid. Negative equity (-AU$3.8m). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (AU$1.54m market cap, or US$1.01m). Minor Risks Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Revenue is less than US$5m (AU$5.0m revenue, or US$3.2m). Announcement • Aug 01
Imagion Biosystems Limited Announces Board Changes Imagion Biosystems Limited announced that Ms Melanie Leydin will join the Board as a Non-Executive Director with the appointment effective from 31 July 2024. Ms Leydin has over 25 years' experience in the accounting profession and over 15 years as a company secretary with extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, re-organization of Companies and shareholder relations. IBX announced that, effective immediately before the conclusion of the General Meeting scheduled on 22 August 2024, Michael Harsh, David Ludvigson and Mark Van Astan, will cease to hold office. (That is, all of the directors who were in office at the time the directors' report (as included in the Company's annual financial report for the financial year ended 31 December 2023) was approved, other than Robert Proulx who acts as Executive Chairman and Managing Director, will cease to hold office). Board Change • Jul 29
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Brett Mitchell was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jun 19
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Non Executive Director David Ludvigson was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • May 06
Imagion Biosystems Limited, Annual General Meeting, May 31, 2024 Imagion Biosystems Limited, Annual General Meeting, May 31, 2024, at 10:01 E. Australia Standard Time. Location: K&L Gates Melbourne, Level 25, 525 Collins Street Melbourne Victoria Australia Agenda: To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditor's Reports in respect of the financial year ended 31 December 2023; to consider adoption of the Remuneration Report; to approve re-Election of Director; and to consider other matters. Reported Earnings • Mar 02
Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.35 loss in FY 2022) Full year 2023 results: AU$0.004 loss per share. Revenue: AU$5.18m (up 69% from FY 2022). Net loss: AU$13.1m (loss widened 33% from FY 2022). New Risk • Jan 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.6m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-AU$1.6m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (AU$7.02m market cap, or US$4.60m). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m). Board Change • Jan 17
No independent directors There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. No independent directors (7 non-independent directors). MD, CEO & Director Isaac Bright was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Nov 15
Imagion Biosystems Limited Approves Election of Isaac Bright as Director Imagion Biosystems Limited announced that at its Extraordinary General Meeting held on 13 November 2023, the shareholders approved Election of Director - Dr. Isaac Bright. New Risk • Oct 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.7m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.6m free cash flow). Negative equity (-AU$1.6m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (AU$15.7m market cap, or US$9.89m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (AU$3.5m revenue, or US$2.2m). Reported Earnings • Sep 03
First half 2023 earnings released: AU$0.007 loss per share (vs AU$0.005 loss in 1H 2022) First half 2023 results: AU$0.007 loss per share (further deteriorated from AU$0.005 loss in 1H 2022). Revenue: AU$690.0k (up 160% from 1H 2022). Net loss: AU$7.68m (loss widened 33% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings. New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$9.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.6m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-AU$1.6m). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m). Market cap is less than US$100m (AU$19.6m market cap, or US$12.7m). New Risk • Aug 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 3.8% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (AU$3.1m revenue, or US$2.0m). Market cap is less than US$100m (AU$20.9m market cap, or US$13.5m). New Risk • Jun 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Revenue is less than US$5m (AU$3.1m revenue, or US$2.0m). Market cap is less than US$100m (AU$16.3m market cap, or US$10.8m). Announcement • Jun 19
Imagion Biosystems Limited Announces CEO Changes Imagion Biosystems Limited announced it has appointed Isaac Bright, MD as CEO, effective 20 June 2023. Dr. Bright is a results-focused business leader and brings to Imagion over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics. Dr. Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics Inc. before its trade sale to iBio Inc. in September 2022. Prior to launching RubrYc, Dr. Bright was Chief Business Officer for molecular diagnostics innovator HealthTell Inc., driving its trade sale to iCarbonX, concomitant with RubrYc’s launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics Inc. and consulting Chief Business Officer for synthetic biology innovator musebio Inc. (currently Incripta Inc.) as it secured its $23 million Series B Preferred financing. Dr. Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016, during which he helped the firm raise €150 million Merieux Participations 2 fund. With Merieux, Dr. Bright led investments and Board representation for Imaginab Inc., Kalila Medical Inc. until its acquisition by Abbott, and Twist Bioscience before its IPO. Dr. Bright’s startup experience began as he built and led QuantaLife Inc.’s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLife’s acquisition by Bio-Rad Laboratories Inc. Previously, Dr. Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic. Dr. Bright earned his bachelor’s degree in biochemistry from Pepperdine University, his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow earning his MBA from the Wharton School at the University of Pennsylvania. The hiring of Dr. Bright follows from the recent announcement on 28 April 2023 regarding the plan for Bob Proulx to retire from the role of CEO, remaining as Chairman of the Board. New Risk • Jun 14
New major risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$15.2m (US$10.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Revenue is less than US$5m (AU$3.1m revenue, or US$2.1m). Market cap is less than US$100m (AU$15.2m market cap, or US$10.3m). Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Dianne Angus was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 26
First half 2022 earnings released: AU$0.005 loss per share (vs AU$0.001 loss in 1H 2021) First half 2022 results: AU$0.005 loss per share (down from AU$0.001 loss in 1H 2021). Net loss: AU$5.76m (loss widened 297% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Board Change • Apr 28
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Non Executive Director Mark Van Asten is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Feb 26
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: AU$0.006 loss per share (up from AU$0.007 loss in FY 2020). Revenue: AU$2.86m (up 5.9% from FY 2020). Net loss: AU$6.02m (loss widened 12% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 22
First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$2.78m (up 20% from 1H 2020). Net loss: AU$1.45m (loss narrowed 17% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 26
Full year 2020 earnings released: AU$0.007 loss per share (vs AU$0.01 loss in FY 2019) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: AU$2.70m (up 8.3% from FY 2019). Net loss: AU$5.36m (loss widened 56% from FY 2019). Is New 90 Day High Low • Feb 18
New 90-day high: AU$0.21 The company is up 72% from its price of AU$0.13 on 18 November 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 8.0% over the same period. Is New 90 Day High Low • Jan 25
New 90-day high: AU$0.21 The company is up 200% from its price of AU$0.07 on 28 October 2020. The Australian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 6.0% over the same period. 
